These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 1549990)

  • 21. Effects of early high-dose streptokinase intravenously on left ventricular function in acute myocardial infarction.
    Bassand JP; Faivre R; Becque O; Habert C; Schuffenecker M; Petiteau PY; Cardot JC; Verdenet J; LaRoze M; Maurat JP
    Am J Cardiol; 1987 Sep; 60(7):435-9. PubMed ID: 3307367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
    Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
    Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study).
    Taylor GJ; Moses HW; Koester D; Colliver JA; Katholi RE; Dove JT; Woodruff RC; Mikell FL; Becker LC; Sheehan FH
    Am J Cardiol; 1993 Nov; 72(14):1010-4. PubMed ID: 8213579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
    JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial.
    Sheehan FH; Braunwald E; Canner P; Dodge HT; Gore J; Van Natta P; Passamani ER; Williams DO; Zaret B
    Circulation; 1987 Apr; 75(4):817-29. PubMed ID: 3103950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction.
    Ribeiro EE; Silva LA; Carneiro R; D'Oliveira LG; Gasquez A; Amino JG; Tavares JR; Petrizzo A; Torossian S; Duprat Filho R
    J Am Coll Cardiol; 1993 Aug; 22(2):376-80. PubMed ID: 8335807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
    Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM
    Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of thrombolytic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patients treated within 4 hours.
    Machecourt J; Dumoulin J; Calop J; Foroni L; Terisse MP; Henon T; Vanzetto G; Denis B; Bassand JP; Cassagnes J
    Eur Heart J; 1993 Jan; 14(1):75-83. PubMed ID: 8432296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A randomized study of streptokinase and recombinant tissue plasminogen activator, with and without heparin, in patients with acute myocardial infarction. The results of GISSI-2/International tPA/SK Mortality Trial].
    Steffensen R; Sandøe E
    Ugeskr Laeger; 1991 Oct; 153(41):2880-3. PubMed ID: 1949301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
    Lancet; 1995 Aug; 346(8971):329-36. PubMed ID: 7623530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Usefulness of combination therapy of hybrid thrombolysis followed by back-up percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction].
    Mukawa H; Sone T; Tsuboi H; Kondo J; Kosokabe T; Uesugi M; Imai H
    J Cardiol; 2001 Apr; 37(4):181-9. PubMed ID: 11337927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.
    Bates ER
    Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator.
    Agostoni A; Gardinali M; Frangi D; Cafaro C; Conciato L; Sponzilli C; Salvioni A; Cugno M; Cicardi M
    Circulation; 1994 Dec; 90(6):2666-70. PubMed ID: 7994806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
    Malcolm AD; Keltai M; Walsh MJ
    Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Holmes DR; Bates ER; Kleiman NS; Sadowski Z; Horgan JH; Morris DC; Califf RM; Berger PB; Topol EJ
    J Am Coll Cardiol; 1995 Sep; 26(3):668-74. PubMed ID: 7642857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.
    Magnani B
    J Am Coll Cardiol; 1989 Jan; 13(1):19-26. PubMed ID: 2491867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
    Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R
    Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
    Maggioni AP; Franzosi MG; Santoro E; White H; Van de Werf F; Tognoni G
    N Engl J Med; 1992 Jul; 327(1):1-6. PubMed ID: 1598096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.